EDGEWISE THERAPEUTICS INC (EWTX) Stock News
NASDAQ:EWTX - Nasdaq - US28036F1057 - Common Stock
EWTX Latest News and Analysis
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
December 19th Options Now Available For Edgewise Therapeutics (EWTX)
Notable Tuesday Option Activity: EWTX, APLD, IAC
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
Edgewise Therapeutics reports promising Phase 2 results for sevasemten, showing reduced muscle damage and well-tolerated safety in Becker muscular dystrophy.
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
MarketBeat Week in Review – 9/23 - 9/27
Stocks had a mostly bullish week as stimulus efforts in the U.S. and China enhanced risk-on sentiment, but next week's jobs report could spark a larger rally
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics is rocketing higher on positive results for its HCM combating treatment and short-covering. Expect volatility in the weeks ahead.
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
One of the biopharma company's heart drugs performs as well as initially hoped.
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Edgewise Therapeutics (NASDAQ:EWTX) just reported results for the second quarte...
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
7 Small-Cap Stocks to Buy for Large-Scale Gains
Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
What sectors outperformed after Trump won the 2016 election, and which outperformed during his term?
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
